|
1
|
Bukowski RM, Ozols RF and Markman M: The
management of recurrent ovarian cancer. Semin Oncol. 34(2 Suppl 2):
S1–S15. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yap TA, Carden CP and Kaye SB: Beyond
chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer.
9:167–181. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laird PW: The power and the promise of DNA
methylation markers. Nat Rev Cancer. 3:253–266. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ozdemir F, Altinisik J, Karateke A,
Coksuer H and Buyru N: Methylation of tumor suppressor genes in
ovarian cancer. Exp Ther Med. 4:1092–1096. 2012.PubMed/NCBI
|
|
5
|
Tahara T and Arisawa T: Potential
usefulness of DNA methylation as a risk marker for digestive cancer
associated with inflammation. Expert Rev Mol Diagn. 12:489–497.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Montavon C, Gloss BS, Warton K, et al:
Prognostic and diagnostic significance of DNA methylation patterns
in high grade serous ovarian cancer. Gynecol Oncol. 124:582–588.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kashuba V, Dmitriev AA, Krasnov GS, et al:
NotI microarrays: Novel epigenetic markers for early detection and
prognosis of high grade serous ovarian cancer. Int J Mol Sci.
13:13352–13377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miki Y, Swensen J, Shattuck-Eidens D, et
al: A strong candidate for the breast and ovarian cancer
susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoshida K and Miki Y: Role of BRCA1 and
BRCA2 as regulators of DNA repair, transcription, and cell cycle in
response to DNA damage. Cancer Sci. 95:866–871. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu J, Lu LY and Yu X: The role of BRCA1 in
DNA damage response. Protein Cell. 1:117–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carser JE, Quinn JE, Michie CO, et al:
BRCA1 is both a prognostic and predictive biomarker of response to
chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol.
123:492–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weberpals JI, Tu D, Squire JA, et al:
Breast cancer 1 (BRCA1) protein expression as a prognostic marker
in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16
correlative study. Ann Oncol. 22:2403–2410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weberpals J, Garbuio K, O’Brien A, et al:
The DNA repair proteins BRCA1 and ERCC1 as predictive markers in
sporadic ovarian cancer. Int J Cancer. 124:806–815. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Quinn JE, James CR, Stewart GE, et al:
BRCA1 mRNA expression levels predict for overall survival in
ovarian cancer after chemotherapy. Clin Cancer Res. 13:7413–7420.
2007. View Article : Google Scholar
|
|
15
|
Bolton KL, Chenevix-Trench G, Goh C, et
al; EMBRACE; kConFab Investigators; Cancer Genome Atlas Research
Network. Association between BRCA1 and BRCA2 mutations and survival
in women with invasive epithelial ovarian cancer. JAMA.
307:382–390. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vencken PM, Kriege M, Hoogwerf D, et al:
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian
cancer patients after first-line chemotherapy compared with
sporadic ovarian cancer patients. Ann Oncol. 22:1346–1352. 2011.
View Article : Google Scholar
|
|
17
|
Chiang JW, Karlan BY, Cass L and Baldwin
RL: BRCA1 promoter methylation predicts adverse ovarian cancer
prognosis. Gynecol Oncol. 101:403–410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Drew Y, Mulligan EA, Vong WT, et al:
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor
AG014699 in human cancers with mutated or methylated BRCA1 or
BRCA2. J Natl Cancer Inst. 103:334–346. 2011. View Article : Google Scholar
|
|
19
|
Wang YQ, Zhang JR, Li SD, et al: Aberrant
methylation of breast and ovarian cancer susceptibility gene 1 in
chemosensitive human ovarian cancer cells does not involve the
phosphatidylinositol 3′-kinase-Akt pathway. Cancer Sci.
101:1618–1623. 2010.PubMed/NCBI
|
|
20
|
Chaudhry P, Srinivasan R and Patel FD:
Utility of gene promoter methylation in prediction of response to
platinum-based chemotherapy in epithelial ovarian cancer (EOC).
Cancer Invest. 27:877–884. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Veeck J, Ropero S, Setien F, et al: BRCA1
CpG island hypermethylation predicts sensitivity to poly(adenosine
diphosphate)-ribose polymerase inhibitors. J Clin Oncol.
28:e563–e566. 2010. View Article : Google Scholar
|
|
22
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
23
|
Laird PW: Cancer epigenetics. Hum Mol
Genet. 14:R65–R76. 2005. View Article : Google Scholar
|
|
24
|
Cheng X and Blumenthal RM: Mammalian DNA
methyltransferases: a structural perspective. Structure.
16:341–350. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bestor TH: The DNA methyltransferases of
mammals. Hum Mol Genet. 9:2395–2402. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vilain A, Apiou F, Dutrillaux B and Malfoy
B: Assignment of candidate DNA methyltransferase gene (DNMT2) to
human chromosome band 10p15.1 by in situ hybridization. Cytogenet
Cell Genet. 82:1201998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rai K, Chidester S, Zavala CV, et al:
Dnmt2 functions in the cytoplasm to promote liver, brain, and
retina development in zebrafish. Genes Dev. 21:261–266. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Goll MG, Kirpekar F, Maggert KA, et al:
Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2.
Science. 311:395–398. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hermann A, Gowher H and Jeltsch A:
Biochemistry and biology of mammalian DNA methyltransferases. Cell
Mol Life Sci. 61:2571–2587. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goll MG and Bestor TH: Eukaryotic cytosine
methyltransferases. Annu Rev Biochem. 74:481–514. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome - biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bai X, Song Z, Fu Y, et al:
Clinicopathological significance and prognostic value of DNA
methyltransferase 1, 3a, and 3b expressions in sporadic epithelial
ovarian cancer. PLoS One. 7:e400242012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaku T, Ogawa S, Kawano Y, et al:
Histological classification of ovarian cancer. Med Electron
Microsc. 36:9–17. 2003. View Article : Google Scholar
|
|
34
|
Matros E, Wang ZC, Lodeiro G, Miron A,
Iglehart JD and Richardson AL: BRCA1 promoter methylation in
sporadic breast tumors: relationship to gene expression profiles.
Breast Cancer Res Treat. 91:179–186. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Knudson AG Jr: Hereditary cancer,
oncogenes, and antioncogenes. Cancer Res. 45:1437–1443.
1985.PubMed/NCBI
|
|
36
|
Esteller M, Silva JM, Dominguez G, et al:
Promoter hypermethylation and BRCA1 inactivation in sporadic breast
and ovarian tumors. J Natl Cancer Inst. 92:564–569. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Geisler JP, Hatterman-Zogg MA, Rathe JA
and Buller RE: Frequency of BRCA1 dysfunction in ovarian cancer. J
Natl Cancer Inst. 94:61–67. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Senturk E, Cohen S, Dottino PR and
Martignetti JA: A critical re-appraisal of BRCA1 methylation
studies in ovarian cancer. Gynecol Oncol. 119:376–383. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang D, Khan S, Sun Y, et al: Association
of BRCA1 and BRCA2 mutations with survival, chemotherapy
sensitivity, and gene mutator phenotype in patients with ovarian
cancer. JAMA. 306:1557–1565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bast RC Jr, Badgwell D, Lu Z, et al: New
tumor markers: CA125 and beyond. Int J Gynecol Cancer. 15(Suppl 3):
274–281. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang J, Wei X, Wu Q, et al: Clinical
significance of the expression of DNA methyltransferase proteins in
gastric cancer. Mol Med Rep. 4:1139–1143. 2011.PubMed/NCBI
|
|
42
|
Qu Y, Mu G, Wu Y, et al: Overexpression of
DNA methyltransferases 1, 3a, and 3b significantly correlates with
retinoblastoma tumorigenesis. Am J Clin Pathol. 134:826–834. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Amara K, Ziadi S, Hachana M, Soltani N,
Korbi S and Trimeche M: DNA methyltransferase DNMT3b protein
overexpression as a prognostic factor in patients with diffuse
large B-cell lymphomas. Cancer Sci. 101:1722–1730. 2010. View Article : Google Scholar
|
